FACULTY

Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew ' s Hospital; Lead for Solid Tumour Research, London, UK. 

Thomas Powles is a Professor of urology cancer at the University of London (2012 onwards) and the Director of Barts Cancer Centre (2017 onwards), which is one of the UKs largest Cancer Centres with over 4000 new cancer patients per year and a CRUK Major Cancer Centre. He trained as an Oncologist at Imperial College.

Dr. Félix Guerrero-Ramos is a prominent Spanish Uro-Oncology specialist and staff urologist at Hospital Universitario 12 de Octubre in Madrid.

He leads the Oncological Urology Unit at ROC Clinic and specializes in bladder and kidney cancer, acting as a principal investigator for numerous international clinical trials. He is also an adjunct professor and holds a PhD in Medicine.

Dr. Daniel Castellano is a Medical Oncologist and specialist in genitourinary cancers. He serves in the Medical Oncology Department at Hospital Universitario 12 de Octubre in Madrid, Spain, where he leads the Genitourinary Tumor Unit and is actively involved in clinical research and advanced oncology care. 

Dr. Castellano’s expertise includes prostate, bladder, and other genitourinary malignancies. He contributes extensively to multidisciplinary clinical trials and precision medicine strategies in advanced cancer management.

Dr. Maroto is Associate Professor of Medicine at the Universitat Autònoma of Barcelona and Professor of the School of Nurses at the same University. Dr. Pablo Maroto graduated in Medicine and Surgery at the University of Santiago de Compostela, La Coruña, and obtained his PhD in 1990 with cum laude qualification in 1998 from the University of Barcelona. He underwent Medical Oncology Residency at the Hospital de la Santa Creu i Sant Pau in Barcelona. To follow, he completed his training as a fellow of Barabara Ann Karmanos Cancer Institute, Detroit, Michigan, from 1997 to 1999. After this period, he joined the Medical Oncology Department of the Hospital de la Santa Creu i Sant Pau in Barcelona as responsible of the Urooncology Clinic. 

Elena Castro is a medical oncologist and group leader at Hospital Universitario 12 de Octubre, in Madrid. Dr Castro received her medical degree and PhD from the University of Salamanca. After training in medical oncology, she completed a fellowship in cancer genetics and prostate cancer at the Institute of Cancer Research and The Royal Marsden Hospital, (London). In 2013, she returned to Spain and joined the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Center (CNIO). Dr Castro is a translational researcher whose interest range from preclinical studies to clinical trials. Her work has focused on the clinical implications of germline and genomic variants in prostate cancer.

Dr. Neeraj Agarwal is a Professor of Medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is a medical oncologist and an internationally recognized physician-scientist in the field of genitourinary cancers, particularly prostate cancer. He has received the SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award, and recognition as a Fellow of the American Society of Clinical Oncology (FASCO).

Dr. Juan A. Vallejo Casas is Director of the Nuclear Medicine Clinical Management Unit (UGC) at Hospital Universitario Reina Sofía, Córdoba, Spain. He is an active member of the Nuclear Endocrinology Working Group of the SEMNIM (Spanish Society of Nuclear Medicine and Molecular Imaging).

His clinical and academic work focuses on nuclear endocrinology, with particular expertise in diagnostic and therapeutic applications of nuclear medicine in endocrine diseases, contributing to multidisciplinary care and advances in molecular imaging.

Dr. Javier Puente, MD, PhD, is a Madrid-based Medical Oncologist and Clinical Researcher specializing in genitourinary (GU) tumors. Based at the Hospital Clínico San Carlos (HCSC) and serving as an Associate Professor at the Complutense University of Madrid (UCM), he focuses on prostate, bladder, and renal cancer research.

Clinical research in GU tumors (prostate, bladder, renal) and active participation in clinical trials. He is heavily involved in national and international research, guideline development, and oncological education.

Dr. Guillermo de Velasco is a medical oncologist with a focus on genitourinary tumors and melanoma. He obtained his medical degree and PhD from the Complutense University of Madrid, and completed his residency in Medical Oncology at University Hospital 12 de Octubre.

His postgraduate training includes research fellowships at the University of Cambridge and Dana-Farber Cancer Institute in Boston, where he further developed his expertise in clinical and translational research.

Manuela Schmidinger is Professor of Medicine and specialises in Internal Medicine, Medical Oncology and Intensive Care Medicine. She is currently leading the clinical and research program for systemic treatment of renal cell carcinoma at the Department of Urology, Medical University of Vienna.

Her research interests include prognostic factors and treatment in RCC, checkpoint inhibitors, tyrosine kinase inhibitor and check point inhibitors-related side effects, and strategies to achieve long-term survival in metastatic RCC.

Prof. Roberto Iacovelli studied medicine at the “Sapienza” University of Rome, Italy. At the same University, he specialized in medical oncology and had the PhD in molecular medicine and human pathology with a focus in genitourinary cancers. He had international experience as fellow at Institute Gustave Roussy in France and he served as oncologist in main referral oncological centres in Italy. Currently, he is a medical oncologist at the Fondazione Policlinico Gemelli IRCCS in Rome, Italy. This is one of the major national hospitals with more than 1500 beds and an active Comprehensive Cancer Center. From December 2022 he is Associate Professor of medical oncology at Sacro Cuore Catholic University of Rome, Italy.

Dr. Jaume Capdevila is a highly experienced senior Medical Oncologist based in Barcelona, Spain, specializing in gastrointestinal, pancreatic, and neuroendocrine tumors at Vall d'Hebron Hospital and the Teknon Cancer Institute. With over 20 years of experience, he is a leading expert in digestive cancer treatment, research, and early-drug development. 

Completed training at the University of Lleida (MBBS, 2001) and Hospital de la Santa Creu i Sant Pau, with a fellowship at Uppsala University Hospital, Sweden. Author of over 80 peer-reviewed articles and active member of ASCO, ESMO, ENETS, and EORTC. He is also involved with GETNE and GETHI.

Patrizia Giannatempo is a Medical Oncology Consultant, since 2006 she has been working at the Instituto Nazionale dei Tumori (INT), Milan, Italy and is dedicated to urological cancers.

She started her career at INT initially as a post-doc fellow in paediatric oncology and then as a resident physician at the Oncology Unit in the genito-urinary oncology programme. Her medical oncology training included an international clinical fellowship at the Royal Marsden Hospital, London, UK.

Michiel van der Heijden is a medical oncologist at the Netherlands Cancer Institute (NKI) since 2013. He obtained his PhD at the University of Amsterdam (2005) on work done in Scott Kern's lab, Johns Hopkins University (Baltimore) and did a laboratory research fellowship with Rene Bernards at the NKI. 

Research by Michiel van der Heijden at the NKI | Netherlands Cancer Institute focuses on optimizing bladder cancer treatments by understanding drug sensitivity, particularly within the neoadjuvant setting

Ignacio Durán is a medical oncologist with interests in clinical and translational research and medical education. He is the Coordinator of the Genitourinary Oncology Program at the Medical Oncology Department in Hospital Universitario Marques de Valdecilla,Santander, Spain. Dr. Durán earned his medical degree in 1997 at the Universidad de Salamanca, Spain, and went on to attain his doctorate in 2005 at the Universidad Complutense, Spain, with highest commendation. Between 2004 and 2007, he completed a fellowship in drug development and genitourinary tumours at the Princess Margaret Cancer Centre in Toronto, Canada, and a master's degree in the teaching of medicine at the University of Toronto.

Morgan Roupret, MD, PhD, is a Professor of Urology at Assistance Publique – Hôpitaux de Paris (APHP) Sorbonne University, Paris, France. He earned his medical degree from Pierre and Marie Curie University, Paris, France, followed by a PhD from Université Paris Cité, Paris, France.

​

Prof. Roupret is actively involved in several esteemed professional societies within the field of urology. He serves as the Chairman of the European Association of Urology (EAU), Section of Oncological Urology (ESOU), where he contributes to advancing uro-oncological research and education